过氧化物酶体增殖激活物受体与15-脂氧合酶-2在前列腺癌组织中的表达及其意义

目的 观察过氧化物酶体增殖激活物受体(PPAR-γ)及15-脂氧合酶-2(15-LOX-2)在前列腺癌中的表达,探讨其意义.方法 采用免疫组织化学方法检测28例前列腺癌组织中PPAR-γ及15-LOX-2蛋白的表达,取26例前列腺增生组织作为对照.结果 PPAR-γ在前列腺癌组表达阳性程度高于前列腺增生组(x2=4.84,P＜0.05);15-LOX-2在前列腺癌组表达阳性程度低于前列腺增生组(x2 =9.00,P＜0.05).T3期前列腺癌PPAR-γ的表达阳性程度明显高于T2期(H=4.103,P＜0.05);T2期与T3期前列腺癌细胞15-LOX-2的表达阳性程度差异无统计学意义(H =0.076,P＞0.05).Gleason评分≥7分前列腺癌PPAR-γ的表达阳性程度明显高于Gleason评分＜7分(H=5.306,P＜0.05);Gleason评分≥7分与Gleason评分＜7分前列腺癌15-LOX-2的表达阳性程度差异无统计学意义(H =0.313,P＞0.05).结论 PPAR-γ蛋白在前列腺癌组织中高表达,并且与病理分期及Gleason评分有关;15-LOX-2在前列腺癌组织中低表达.它提示PPAR-γ和15-LOX-2与前列腺癌发生与发展有关.     

Cav-1 mRNA、S100A4 mRNA 和 CD31 的表达与前列腺癌转移及生存率关系的研究

目的 研究前列腺癌组织中Cav-1 mRNA、S100A4 mRNA和CD31的表达,探讨其与前列腺癌转移及生存率的关系. 方法 选取2004年1月至2006年5月行前列腺癌根治术切除的癌组织标本42例和癌旁组织12例.患者年龄58 ～ 86岁,平均(71.6±7.6)岁.Gleason评分≤6分17例,7分12例,≥8分13例.TNM分期:T116例,T29例,T311例,T46例.骨转移8例,无骨转移34例.术前PSA＜4μg/L 4例,4～ 10 μg/L 10例,＞10 μg/L 28例.12例前列腺癌旁组织作为对照组,取自距离肿瘤1 ～2 cm或另一叶(镜下验证无癌细胞)的正常前列腺组织.采用原位杂交法检测42例前列腺癌切除标本和12例癌旁组织中Cav-1 mRNA、S100A4 mRNA的表达;用CD31标记血管内皮细胞,计数肿瘤组织的微血管密度( microvessel density,MVD);结合临床资料分析三者与前列腺癌Gleason评分、TNM分期、PSA值及有无骨转移等特性的关系. 结果 前列腺癌组织中Cav-1 mRNA 和S100A4 mRNA阳性表达率分别为35.7％ (15/42)和47.6％ (20/42),癌旁组织分别为0和8.3％(1/12),各组比较差异均有统计学意义(P＜0.05).Cav-1 mRNA和S100A4 mRNA阳性表达率均与前列腺癌Gleason评分、TNM分期及骨转移呈正相关.Cav-1 mRNA、S100A4 mRNA阴性表达者MVD分别为(62.8±10.4)/mm2和(63.3±12.0)/mm2,阳性表达者分别为(83.5±6.7)/mm2和(77.9±11.0 )/mm2,组间比较差异均有统计学意义(P＜0.05).Cav-1 mRNA表达阳性组和阴性组5年生存率分别为46.7％ (7/15)、85.2％ (23/27),组间比较差异有统计学意义(P＜0.05).S100A4 mRNA表达阳性组和阴性组5年生存率分别为50.0％ (10/20)、90.9％( 20/22),组间比较差异有统计学意义(P＜0.05). 结论 Cav-1 mRNA和S100A4 mRNA阳性表达、MVD增高可能与前列腺痛进展、骨转移有关.Cav-1、S100A4均可能促进前列腺癌微血管形成,导致癌细胞骨转移,降低患者生存质最和生存率.     

经腹腔途径腹腔镜前列腺癌根治术后切缘阳性的影响因素分析

目的探讨经腹腔途径腹腔镜前列腺癌根治术后切缘阳性的相关影响因素。方法 2009年9月至2014年5月,采用经腹腔途径行腹腔镜下前列腺癌根治术61例。患者年龄56~74岁,平均71岁。术前均经直肠超声引导下穿刺病理证实前列腺癌诊断。通过回顾性研究了解术前血清前列腺特异性抗原(PSA)、穿刺后Gleason评分、穿刺针数阳性百分率,术前TNM分期对手术切缘阳性的影响。结果61例前列腺癌患者术后切缘阳性率19.7%(12/61),病理分期与手术切缘阳性成正相关(γ=0.311,P=0.001),且对手术切缘阳性有统计学意义(χ~2=16.32,P=0.001);对于手术切缘阳性率,术前血清PSA20ng/ml组与血清PSA≥20ng/ml组比较,差异有统计学意义(χ~2=7.32,P=0.007);穿刺后Gleason评分7分组与Gleason评分≥7分组差异无统计学意义了(χ~2=1.43,P=0.23);穿刺针数阳性百分率,50%组与≥50%组差异有统计学意义(χ~2=4.32,P=0.017)。结论穿刺后TNM分期,血清PSA水平,穿刺阳性百分率的差异对手术切缘阳性有统计学意义。前列腺癌穿刺标本Gleason评分与术后病理切缘之间无相关性。     

SATB-1基因在前列腺癌中的特异表达及临床意义

目的 探讨特异性核基质结合区结合蛋白(SATB-1)在前列腺癌中的表达及临床意义.方法 收集前列腺增生、前列腺癌无骨转移、前列腺癌骨转移各30例患者的前列腺组织标本,采用免疫组织化学S-P法检测SATB-1的表达,并结合临床病理因素进行分析.结果 SATB-1表达阳性率在前列腺增生组织为0(0/30),前列腺癌组织为86.7%(52/60),两组比较差异有统计学意义(P<0.05);前列腺癌Gleason评分2～4分者SATB-1表达阳性率为76.5%(13/17),5～7分者为85.0%(17/20),8～10分者为95.7%(22/23),组间比较差异无统计学意义(P>0.05).采用双评分半定量法对SATB-1表达强度进行评分,经秩和检验SATB-1表达强度在前列腺癌无骨转移组与前列腺癌骨转移组间比较差异有统计学意义(P<0.05).SATB-1表达强度在前列腺癌不同Gleason评分组间比较差异有统计学意义(P<0.05),表达强度随Gleason评分的增加而增强.结论 SATB-1仅在前列腺癌组织中表达,且在Gleason评分高、有骨转移的前列腺癌组织中表达强度明显增加.SATB-1有望作为前列腺癌诊断和判断预后的有效指标.     

CD147在前列腺癌组织中的表达及意义

目的 研究细胞外基质金属蛋白酶诱导分子CD147在前列腺癌组织的表达情况,探讨其与前列腺癌临床病理及预后的关系.方法 免疫组织化学S-P法检测62例前列腺癌和15例前列腺增生组织中CD147的表达情况.62例癌组织局限于包膜内38例,有包膜外侵犯24例;Gleason评分＜7分36例,＞7分26例;临床分期T1 4例,T2a17例,T2b 20例,T321例;病理分级瘤样增生2例,高分化9例,中分化23例,低分化28例.对CD147与前列腺癌临床病理的关系进行统计学分析.结果 62例前列腺癌组织中CD147表达阳性51例(82.3%),15例前列腺增生组织CD147表达阳性2例(13.3%),2组比较差异有统计学意义(P＜0.05).CD147蛋白表达与肿瘤的TNM分期、包膜侵犯、Gleason评分和病理分级均相关(P值均＜0.05).结论 CD147蛋白在前列腺癌组织的表达与肿瘤恶性程度和侵袭力密切相关,对前列腺癌的诊断和预后评估有重要价值.     

HSF1和4-HNE的过度表达对前列腺癌恶性表型的影响

目的:探讨热休克转录因子1(HSF1)和四羟基壬烯(4-HNE)在前列腺癌组织中的表达及其临床意义。方法:采用免疫组化方法检测50例前列腺癌组织及50例良性前列腺增生组织中HSF1和4-HNE的表达,分析HSF1和4-HNE的表达与Gleason分级之间的关系。结果:HSF1在良性前列腺增生组织中阳性表达率较低,为4.0%。50例前列腺癌组织中HSF1阳性表达率在高、中、低分化癌中分别为37.5%、50.0%、75.0%,呈明显上升趋势,两组HSF1阳性表达差异有统计学意义(P=0.001)。HSF1的阳性表达率在不同Gleason分级间差异有统计学意义(P=0.025)。4-HNE在良性前列腺增生组织中阳性表达率较低,仅为6.0%。50例前列腺癌组织中4-HNE阳性表达率在高、中、低分化癌中分别为81.3%、92.9%、100.0%,呈上升趋势,两组4-HNE表达的差异有统计学意义(P=0.001)。4-HNE的阳性表达率在不同Gleason分级间差异有统计学意义(P=0.029)。前列腺癌组织中HSF1和4-HNE阳性表达呈正相关(r=0.947,P=0.001)结论:HSF1和4-HNE的过度表达与前列腺癌的分级相关,可以作为判断前列腺癌恶性程度具有重要参考价值的新生物学标记物。     

前列腺癌组织中雄激素受体的表达

目的 研究雄激素受体(AR)在前列腺癌(PCa)组织中的表达，探讨AR与PCa的关系。方法 采用免疫组织化学SP法检测60例PCa标本和40例正常前列腺组织AR的表达。结果 PCa组AR表达明显低于正常前列腺对照组(p＝0．001)；正常对照组前列腺腺上皮的AR表达明显高于间质（P＝0．0001)，阳性染色颗粒主要分布在前列腺的腺上皮的细胞核中。早期前列腺癌AR阳性表达率高于晚期(P＝0．0227)。高、中分化癌的AR阳性表达率高于低分化癌(P＝0．0403)。结论 PCa组织中的AR阳性表达率低于正常前列腺组织。AR的表达与肿瘤的分期、分级相关。     

前列腺癌分期方法的临床评价

目的 :探讨临床参数对前列腺癌分期的临床意义。　方法 :通过病理诊断、MRI检查及全身骨扫描对 112例经前列腺活检病理证实的前列腺癌进行分期 ,结合血清前列腺特异抗原 (PSA)、穿刺后Gleason评分、穿刺阳性针数百分率评价其临床意义。　结果 :112例前列腺癌中 ,血清PSA、Gleason评分、穿刺阳性针数百分率对前列腺癌分期有显著相关性 (r=0 .6 98,r=0 .6 74 ,r=0 .6 71,P均 <0 .0 0 1) ,但对B期和C期前列腺癌的诊断差异无显著性 (χ2=2 .6 75 ,P =0 .0 96 ;χ2 =0 .70 4 ,P =0 .4 0 1) ,血清PSA较Gleason评分和穿刺阳性针数百分率对D期的诊断差异有显著性 (χ2 =5 .135 ,P =0 .0 2 3;χ2 =4 .5 93,P =0 .0 32 )。血清PSA、Gleason评分和穿刺阳性针数百分率的敏感性分别为 76 .7%、83.3%和 77.8% ,特异性为 5 0 %、77.3%和 5 4 .5 % ,准确性为 71.4 %、82 .1%和 73.2 %。　结论 :血清PSA、Gleason评分、穿刺阳性针数百分率可预测前列腺癌的分期 ,穿刺后Gleason评分对前列腺癌分期的预测较血清PSA和穿刺阳性针数百分率更准确。血清PSA对远处转移性前列腺癌的预测更有意义     

前列腺特异性膜抗原在前列腺癌组织中的表达与临床病理特征的关系及预后价值

目的 检测前列腺特异性膜抗原(prostate specific membrane antigen, PSMA)在前列腺癌组织中的表达情况,分析其与病人临床病理特征的关系及预后价值。方法 2015年1月～2018年9月我院诊治的前列腺癌病人280例,前列腺增生病人40例,收集石蜡切片标本,行免疫组织化学染色检测PSMA表达情况,分析与临床病理特征的相关性,采用COX比例风险模型分析影响病人无生化复发生存率(BRFS)的独立预后因子。结果 280例前列腺癌组织中,共216例(77.1%)PSMA表达阳性;40例前列腺增生组织中,17例(42.5%)PSMA表达阳性,阳性率低于前列腺癌组,差异有统计学意义(P<0.05)。存在淋巴结转移、Gleason评分>7分的病人PSMA阳性表达率较无淋巴结转移、Gleason评分≤7分高,差异有统计学意义(P<0.05)。PSMA阳性表达、淋巴结转移是影响前列腺癌病人BRFS的独立预后因子(P<0.05)。结论 前列腺癌组织中PSMA呈现高表达,与淋巴结转移、Gleason评分密切相关,可作为影响病人无生化复发生存的独立预后因...     

Ets-1在前列腺癌组织中的表达及其临床意义

目的 探讨原癌基因Ets-1在前列腺组织中的表达及其与前列腺癌组织学分级的关系.方法 利用免疫组化法检测Ets-1在4例正常前列腺组织,12例良性前列腺增生组织和53例前列腺癌组织中的表达.结果 Ets-1蛋白的阳性表达在前列腺癌细胞的胞浆及胞核内均可见,79%的前列腺癌组织中Ets-1呈阳性表达,而在良性前列腺组织细胞中无表达或仅有微弱表达,差异有显著性意义(P<0.05).在前列腺癌组织中,Gleason评分高危组Ets-1阳性表达率明显高于Gleason中危组和低危组(P<0.05).结论 与良性前列腺组织对照相比,Ets-1有肿瘤特异性,其表达与前列腺癌的组织学分级相关,可作为前列腺癌病变程度及临床预后判断的一个分子标志.     

AMACR(P504S)、P63、34βE12联合检测在前列腺癌早期诊断中的应用

目的:探讨AMACR(P504S)、P63、34βE12联合检测在前列腺癌(PCa)早期诊断中的临床应用价值。方法:应用即用型组合式单克隆抗体和双酶标记的免疫组化MaxvisionTM一步法检测42例PCa、12例高级别前列腺上皮内瘤变(HGPIN)和30例良性前列腺增生(BPH)穿刺活检标本中AMACR、P63、34βE12的表达情况。比较Glea-son评分各组中AMACR阳性表达情况。结果:AMACR、P63、34βE12抗原在PCa和BPH穿刺标本中的表达差异均有极显著性(P<0.01),PCa组织中AMACR阳性表达率为100%,无P63和34βE12表达;BPH组织中均无AM-ACR表达,P63和34βE12均高表达。HGPIN中AMACR的阳性表达率(91.67%)与BPH差异有极显著性(P<0.01),与PCa差异无显著性(P>0.05);P63和34βE12阳性表达率HGPIN(100%)与PCa差异有极显著性(P<0.01),而与BPH差异无显著性(P>0.05)。AMACR表达强弱与PCa的Gleason评分无关(P>0.05)。结论:AMACR是PCa高度敏感和特异的标志物,P63和34βE12联合标记基底细胞的特异性高,3者联合检测能增加前列腺穿刺活检标本诊断的准确性,在PCa早期诊断中具有重要的临床应用价值。     

Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate

Overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in combination with absence of basal cell markers [ie, p63 and high molecular weight cytokeratin (HMWCK)] is typical of classic acinar prostatic adenocarcinoma. We studied the expression and diagnostic utility of p63/HMWCK/AMACR immunohistochemical cocktail staining in ductal adenocarcinoma and cribriform Gleason pattern 4 acinar prostate cancer and compared it to noncribriform Gleason pattern 4 acinar prostate cancer. One to 4 representative formalin-fixed paraffin-embedded archival tissue blocks from 62 radical prostatectomy specimens harboring prostate cancer of ductal (n=51), cribriform Gleason pattern 4 acinar (n=27), and noncribriform Gleason pattern 4 acinar adenocarcinoma (n=48) were included in this study. Immunohistochemistry was performed using a triple stain of AMACR, p63, and HMWCK. Only staining that was moderate or strong was considered positive. The percentage of staining intensity and the presence of occasional basal cells positive with p63/HMWCK were recorded in each histologic type of prostatic adenocarcinoma. Seventy-seven percent of ductal prostatic adenocarcinoma, 67% of cribriform acinar prostatic carcinoma, and 81% of noncribriform acinar prostatic carcinoma showed positive staining for AMACR. There was no statistically significant difference between AMACR staining among the 3 histologic types, although there was a trend for noncribriform acinar prostatic carcinoma to have greater expression of AMACR than cribriform acinar prostatic carcinoma (P=0.07). Staining was often heterogeneous, varying in staining intensities within the same histologic type of carcinoma. Basal cells were detectable by p63 and HMWCK in a patchy fashion in 31.4% (16/51) of ductal and 29.6% (8/27) of cribriform acinar carcinomas compared with 2.1% (1/48) of noncribriform acinar carcinomas. In summary: (1) the majority of prostatic ductal and cribriform acinar carcinomas strongly expressed AMACR, however, subpopulations of these prostatic carcinoma were either completely negative or only weakly positive; (2) AMACR staining was often heterogeneous in intensity in the same histologic type of tumor, even within the same case; (3) patchy basal cell staining in noncribriform acinar prostatic carcinoma is rare. In contrast, remnants of basal cells identified by p63/HMWCK were seen in a patchy fashion in a significant minority of both ductal and cribriform acinar prostatic adenocarcinoma, which most likely represents intraductal spread of tumor.     

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy

Modulation of androgen receptor (AR) expression during neoadjuvant endocrine therapy in human prostates of patients with localized prostate cancer was investigated by immunohistochemistry. In 8 of 15 untreated prostatectomy specimens, the majority of prostatic glandular cells displayed nuclear immunostaining for AR, whereas only 1 of 26 pretreated cases displayed a similar glandular AR expression. Expression of AR in the prostatic stromal compartment of nontreated cases proved to be quite heterogeneous, since 4 of the 15 (27%) examined specimens did not show stromal AR expression. After preoperative neoadjuvant therapy, this value was 68%, although this difference did not reach statistical significance. Prostatectomy specimens of the treated patients contained carcinomas with a higher Gleason score than those of untreated patients. AR expression in carcinomas of treated patients was diminished (P=0.05), which may be attributed to their relatively lower differentiation grade. The data strongly suggest that neoadjuvant hormone therapy reduces AR expression by nonneoplastic prostatic glandular cells and carcinoma cells by a selective, but incomplete, elimination of AR-positive cells. © 1996 Wiley-Liss, Inc.     

Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer

BACKGROUND: Alpha-methylacyl-CoA racemase (AMACR) is strongly expressed in prostate cancer with variable expression in high-grade prostatic intraepithelial neoplasia (HGPIN) and low expression in normal prostate. We examined whether AMACR expression in HGPIN and normal tissue was associated with subsequent diagnosis of cancer or proximity to a cancer focus. METHODS: Needle core biopsies from 45 patients with isolated HGPIN, 12 radical prostatectomy (RP) specimens with prostatic carcinoma and 6 cystoprostatectomies without prostatic carcinoma were immunostained for AMACR. Among patients with HGPIN, 23 (cases) showed cancer on a later biopsy and 22 (controls) had no cancer with at least 3 consecutive negative biopsies. RESULTS: In the biopsy set, the mean AMACR expression per gland in the normal compartment of the cases (0.29) was significantly higher than the controls (0.21) (P = 0.0006). In the RP set, normal glands near a cancer focus had higher mean AMACR expression than those that were distant (P = 0.0006). There was no difference within the HGPIN compartment between cases and controls in the biopsies, or between near and distant glands in the RP set. Mean AMACR staining of normal glands in the cystoprostatectomy specimens was significantly lower than in normal glands in close proximity to a cancer focus. CONCLUSIONS: Higher expression of AMACR in normal glands near a focus of cancer, as well as in the subjects eventually showing cancer, suggests a possible field effect in prostatic carcinogenesis. AMACR expression in normal glands therefore might be a useful predictor for repeat biopsy outcomes or as an intermediate endpoint in chemoprevention studies.     

Ku70蛋白在前列腺癌中表达的临床研究

目的 探讨Ku70蛋白表达与前列腺癌Gleason评分及前列腺特异抗原(prostate specific antigen,PSA)的关系.方法 采用HE染色观察组织学形态,免疫组化SP法检测前列腺癌组织中Ku70蛋白表达,按前列腺癌Gleason评分和血清PSA值分组,比较各组间Ku70蛋白表达水平.结果 58例前列腺癌标本中Ku70蛋白均呈阳性表达,其表达强度与前列腺癌Gleason评分和血清PSA呈明显负相关.结论 Ku70蛋白表达水平能帮助判断前列腺癌预后及评价治疗效果,可用于临床指导个体化治疗.     

Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients

BACKGROUND: Oncogene amplification and chromosomal anomalies are found in many solid tumors and are often associated with aggressiveness of cancer. We evaluated the frequency and the association of c-myc and androgen receptor (AR) gene amplification and gain of chromosome 8 or X in prostate cancer in Japanese patients. METHODS: We examined a total of 42 prostate cancer specimens, using fluorescence in situ hybridization (FISH). Dual-labeling hybridization with a directly labeled centromere probe for chromosome 8 or X together with a probe for the c-myc or AR locus was performed. RESULTS: Gain of chromosome 8 was identified in 54.8% of specimens and was associated with Gleason sum and nuclear anaplasia in untreated prostate cancers. c-myc gene amplification was found in 14.3% of specimens. Gain of chromosome X was identified in 42.9% of specimens. AR gene amplification was detected in 0 of 37 untreated prostate cancers, but in 1 of 5 hormone-refractory prostate cancers. CONCLUSIONS: Our results suggest that c-myc and AR gene amplification and gain of chromosome 8 or X may be associated with the development and progression of prostate cancers. These results obtained in Japanese cases are consistent with the results observed in prostate cancer in Western countries.     

Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score

OBJECTIVE: To evaluate the effect of extended 12-core prostate biopsy in improving the detection rate of prostate cancer and increasing the accuracy of Gleason score. METHODS: This study included 113 patients who underwent TRUS-guided lateral sextant biopsy (group I) and 176 patients who underwent extended 12-core biopsy (group II). Inclusion criteria for prostate biopsy were elevated serum PSA levels (>3.0 ng/ml) and/or suspicious digital rectal examination (DRE). RESULTS: Clinical characteristics were similar in both groups. Cancer was detected in 28 (24.8%) and 64 (36.4%) patients in group I and II respectively, chi2=4.26, p=0.039. Among patients with cancer in group I, 14 were treated by radical prostatectomy (RP). The median Gleason sum was 6 (range 3-8) and 7 (range 5-9) for needle and prostatectomy specimens respectively. There was an agreement between the biopsy and prostatectomy Gleason sum in 7 (50%) patients while the biopsy Gleason sum was lower in 7 (50%) cases. Among patients with cancer in group II, 27 were treated by RP. The median and the range of Gleason sum was the same for needle and prostatectomy specimen (median 6, range 4-9). There was an agreement between the biopsy and prostatectomy specimen in 23 (85.2%) patients while the biopsy sum was lower than prostatectomy in 4 (14.8%) patients. The agreement between the biopsy and prostatectomy specimen was significantly higher in group II (82.5%) than group I (50%), Fisher's Exact Test, p=0.026. CONCLUSION: Extended 12-core prostate biopsy significantly increases both the detection rate of prostate cancer and the accuracy of biopsy Gleason score.     

组蛋白去乙酰化酶在前列腺癌组织中表达的意义

目的 研究组蛋白去乙酰化酶(HDAC)在前列腺癌(PCa)组织中表达的意义。 方法 经病理确诊PCa组织标本37例,患者年龄57 ～ 88岁,平均73岁。穿刺前t-PSA 3.13～2000 ng/ml,中位数81.69 ng/ml。Gleason评分≤7分13例,＞7分24例。以27例良性前列腺增生(BPH)组织标本为对照组,患者年龄52～84岁,平均69岁。穿刺前t-PSA 1.11～55.07 ng/ml,中位数10.93 ng/ml。应用蛋白质印迹法和比色法酶活性试剂盒检测HDAC在PCa和BPH组织中的表达及活性,比较PCa和BPH组织中酶活性差异,分析PCa组织中HDAC表达水平与血清PSA和Gleason评分的相关性。 结果 PCa组织中HDAC1、HDAC2、HDAC3和HDAC4表达率分别为57％、68％、84％和73％,PCa组织中HDAC活性（平均A值0.725）明显高于BPH组织（平均A值0.451）,2组比较差异有统计学意义（P＜0.05）;PCa组织中HDAC表达与血清PSA、Gleason评分无相关性。 结论 PCa 组织中存在HDAC表达水平升高和酶活性增强,提示HDAC可能成为治疗PCa的新靶点。     

蛋白激酶Cε在前列腺癌组织中表达的临床意义

目的 探讨蛋白激酶C ε(PKCε)在不同病理类型前列腺组织中的表达及与前列腺癌病理分级、分期的关系。 方法 正常前列腺(NP)组织标本10例、前列腺增生(BPH)组织标本10例、癌旁(PC)组织标本10例、前列腺癌(PCa)组织标本43例。免疫组化法检测各组织中PKCε的表达情况,分析PKCε表达与不同病理类型及PCa分级、分期的关系。 结果 PCa组PKCε表达阳性27例,BPH组无阳性表达,NP组1例,PC组2例,差异有统计学意义(P＜0.05)。PCa组Gleason评分≥8分组中PKCε表达阳性12/13例,2～4分组4/10例,5～7分组11/20例,组间差异有统计学意义(P＜0.05)。T3期PKCε表达阳性10/12例,T4期9/10例,T1、T2期分别为1/6例和7/15例,高分期与低分期组PKCε表达差异有统计学意义(P＜0.05)。PCa转移组PKCε表达阳性9/10例,未转移组18/33例,组间差异有统计学意义(P＜0.05)。PCa患者血清PSA≤20 ng/ml者PKCε表达阳性7/15例,＞20 ng/ml组20/18例,组间差异无统计学意义(P＞0.05)。 结论 PCa组织中PKCε的表达率较高,并且与PCa病理分级、分期呈正相关,临床上可考虑作为PCa预后因子之一。